Cencora (COR) Earnings Date & Reports

Cencora's Q2 revenue totaled $78.4 billion, a 3.8% increase from $75.5 billion in the prior-year quarter but below analyst consensus of approximately $80.8 billion. Growth was led by U.S. Healthcare Solutions at $68.8 billion (up 2.9%), driven by specialty and GLP-1 volumes, offset by price declines and customer losses; International Healthcare Solutions at $7.6 billion (up 13.0%, or 7.2% constant currency); and Other at $2.1 billion (up 5.1%).

Adjusted gross profit rose 15.7% to $3.4 billion (4.31% margin, up 45 basis points), while adjusted operating expenses increased 22.5% to $2.1 billion due to OneOncology integration. Adjusted operating income grew 6.0% to $1.3 billion (1.61% margin). Adjusted diluted EPS of $4.75 beat the year-ago $4.42 by 7.5% but missed estimates of $4.80-$4.81. GAAP EPS hit $8.40, inflated by the $1.1 billion OneOncology gain.

Guidance was updated upward for adjusted diluted EPS to $17.65-$17.90, with revenue growth now at 4%-6% (U.S. 4%-6%, International 8%-10%). Adjusted operating income growth raised to 12%-14%.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener today to enhance your research process.

Market Reaction and Investor Sentiment

Cencora shares dropped over 17% on May 6, 2026, closing down around 16.7%-18% after the pre-market release, underperforming a broader market up 1.4%. The selloff stemmed from the revenue miss and commentary on U.S. headwinds—manufacturer price reductions, oncology customer losses, and faster brand-to-generic shifts—despite the EPS beat and raised guidance. Sentiment turned cautious, with focus shifting to near-term demand softness outweighing profitability gains from acquisitions like OneOncology.

Forward Outlook and Key Factors to Monitor

Following Q2 results, Cencora's raised full-year adjusted EPS guidance to $17.65-$17.90 underscores margin expansion potential from specialty pharmaceuticals and the OneOncology integration, now contributing to U.S. Healthcare Solutions growth.

Investors should track U.S. segment dynamics, including GLP-1 demand amid competition and reimbursement changes, alongside recovery from customer losses and pricing pressures. International Healthcare Solutions remains a bright spot, with 8%-10% revenue growth expected from European distribution efficiencies.

Other key watches include progress on $1 billion share repurchases by year-end, adjusted free cash flow around $3 billion supporting debt reduction (net interest ~$485 million), and capital expenditures near $900 million. Broader factors like regulatory developments in drug distribution and M&A (mergers and acquisitions) activity will shape execution. Steady dividend hikes, like the recent $0.60 per share, signal capital return commitment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations